X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercepharma.com/pharma/alder-wanted-ex-u-s-partner-for-its-cgrp-drug-but-lundbeck-went-for-whole-thing
https://endpts.com/lundbecks-deborah-dunsire-didnt-just-want-an-ex-us-deal-for-alders-migraine-drug-she-wanted-the-whole-world/
https://www.fiercebiotech.com/biotech/lundbeck-pens-2b-alder-takeover-to-boost-brain-disease-pipeline
http://www.globenewswire.com/news-release/2019/07/08/1879405/0/en/Alder-BioPharmaceuticals-to-Showcase-14-New-Data-Presentations-Demonstrating-Eptinezumab-s-Migraine-Prevention-and-Quality-of-Life-Impact-at-American-Headache-Society-Meeting.html
https://www.fiercepharma.com/pharma/not-quite-a-year-into-launch-amgen-wants-to-can-its-aimovig-collaboration-novartis-lawsuit
https://www.biopharmadive.com/news/amgen-launches-tv-spot-for-aimovig-in-tight-cgrp-market/539942/
https://www.fiercepharma.com/pharma/amgen-s-quick-aimovig-launch-has-implications-for-lilly-teva-and-alder-analyst
https://www.marketwatch.com/press-release/pre-market-research-reports-on-biotech-stocks----agenus-aimmune-therapeutics-akebia-therapeutics-and-alder-biopharma-2018-07-25
https://www.fiercepharma.com/pharma/icer-to-payers-go-easy-cgrp-restrictions-if-pricing-stays-reasonable
https://globenewswire.com/news-release/2018/06/29/1531751/0/en/Alder-BioPharmaceuticals-Presents-New-One-Year-Data-for-Eptinezumab-from-PROMISE-1-Phase-3-Trial-Demonstrating-Long-Term-Efficacy-in-Episodic-Migraine.html
Market Place
Share 
